Skip to main content
SpringerLink
Log in

Comparative Tolerability of Systemic Treatments for Plaque-Type Psoriasis

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Psoriasis is a chronic, debilitating skin condition that affects millions of people and is attributed to both genetic and environmental factors. Topical therapy is generally considered to be the first-line treatment of psoriasis. However, many patients do not respond to topical therapy or have disease so extensive that topical therapy is not practical. For these patients, systemic therapy is indicated. Presently, there are four available systemic treatments, psoralen with ultraviolet A (PUVA),methotrexate, oral retinoids (acitretin), and cyclosporin. Unfortunately, all of these treatments have significant potential adverse effects. PUVA may acutely cause nausea, pruritis and sunburn. More chronic and concerning is the development of PUVA lentigines, ocular complications and skin cancer. Nonmelanoma skin cancer has been directly linked to PUVA; however, the association with melonoma is more elusive. Methotrexate use most notably carries the risk of hepatic fibrosis and cirrhosis, which is not always evident on liver function tests. Other more rare, but potentially life-threatening adverse effects include pancytopenia, lymphoproliferative disorders and acute pneumonitis. The addition of folic acid may help to reduce the risk of increasing liver enzymes and haematological toxicity seen in those taking methotrexate. Both methotrexate and oral retinoids are teratogenic and should never be used in pregnancy. Oral retinoids are probably the least effective available systemic medication for the treatment of plaque psoriasis. The effects are improved with the addition of other systemic therapies. Acitretin has replaced the formerly used etretinate primarily because of the significantly shorter half-life. The adverse effects are generally mild and reversible, making the drug fairly safe for long-term use. The most commonly seen adverse effects include elevated serumlipids, generalised xerosis and alopecia. Bony abnormalities, while somewhat controversial, have also been described and include diffuse idiopathic skeletal hyperostosis, skeletal calcifications and osteoporosis. Cyclosporin is the most recently approved systemic medication for plaque psoriasis. The nephrotoxicity associated with the use of cyclosporin can be minimised when used in lower doses and for a limited duration. Hypertension is usually mild and can be seen in up to about one-third of patients receiving long-term therapy. Cutaneous and internal malignancies have also been reported with cyclosporin and tend to be correlated with duration of treatment. In this review, we will examine the potential adverse effects with these US Food and Drug Administration-approved treatments in adults, with specific emphasis on the controversies that surround long-term therapy with these agents and their cumulative adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Morison WL. PUVA photochemotherapy: In: Kulp-Shorten CL, Wolverton SE, editors. Comprehensive dermatologic drug therapy. Philadelphia (PA): WB Saunders Company, 2001: 311–25

    Google Scholar 

  2. Callen JP. Methotrexate. In: Kulp-Shorten CL, Wolverton SE, editors. Comprehensive dermatologic drug therapy. Philadelphia (PA): WB Saunders Company, 2001: 147–64

    Google Scholar 

  3. Nguyen EQH. Systemic retinoids. In: Kulp-Shorten CL, Wolverton SE, editors. Comprehensive dermatologic drug therapy. Philadelphia (PA): WB Saunders Company, 2001: 269–310

    Google Scholar 

  4. Koo J. Cyclosporine and related drugs. In: Kulp-Shorten CL, Wolverton SE, editors. Comprehensive dermatologic drug therapy. Philadelphia (PA): WB Saunders Company, 2001: 205–29

    Google Scholar 

  5. de Jong EM. The course of psoriasis. Clin Dermatol 1997; 15(5): 687–92

    Article  PubMed  Google Scholar 

  6. Khachemoune A, Phillips TJ. Current treatment options in psoriasis. Hosp Pract (Off Ed) 2000; 35(7): 93–4, 107

    CAS  Google Scholar 

  7. Zitnik RJ, Cooper Jr JA. Pulmonary disease due to antirheumatic agents. Clin Chest Med 1990; 11(1): 139–50

    PubMed  CAS  Google Scholar 

  8. Gonzalez E. PUVA for psoriasis. Dermatol Clin 1995; 13(4): 851–66

    PubMed  CAS  Google Scholar 

  9. Peters BP, Weissman FG, Gill MA. Pathophysiology and treatment of psoriasis. Am J Health Syst Pharm 2000; 57(7): 645–59

    PubMed  CAS  Google Scholar 

  10. Murray HE, Anhalt AW, Lessard R, et al. A 12-month treatment of sever psoriasis with acitretin: results of a Canadian open multicentre study. J Am Acad Dermatol 1991; 24(4): 598–602

    Article  PubMed  CAS  Google Scholar 

  11. Abel EA. Phototherapy: UVB and PUVA. Cutis 1999; 64(5): 339–42

    PubMed  CAS  Google Scholar 

  12. Bolognia JL, Freije L, Amici L, et al. Rectal suppositories of 8-methoxsalen produce fewer gastrointestinal side effects than the oral formulation. J Am Acad Dermatol 1996; 35(3 Pt 1): 424–7

    Article  PubMed  CAS  Google Scholar 

  13. Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am J Med 1999; 107(6): 595–605

    Article  PubMed  CAS  Google Scholar 

  14. Filipe P, Emerit I, Alaoui YA, et al. Oxyradical-mediated clastogenic plasma factors in psoriasis: increase in clastogenic activity after PUVA. Photochem Photobiol 1997; 66(4): 497–501

    Article  PubMed  CAS  Google Scholar 

  15. Dowdy MJ, Nigra TP, Barth WF. Subacute cutaneous lupus erythematosus during PUVA therapy for psoriasis: case report and review of the literature. Arthritis Rheum 1989; 32(3): 343–6

    Article  PubMed  CAS  Google Scholar 

  16. Matovic L, Poljacki M, Duran V, et al. The Koebner phenomenon, a prognostic sign of PUVA therapy effectiveness in patients with psoriasis vulgaris: yes or no? Med Pregl 1999; 52(11-12): 437–40

    PubMed  CAS  Google Scholar 

  17. Georgouras KE, Zagarella SS, Cains GD, et al. Systemic treatment of severe psoriasis. Australas J Dermatol 1997; 38(4): 171–80

    Article  PubMed  CAS  Google Scholar 

  18. See JA, Weller P. Ocular complications of PUVA therapy. Australas J Dermatol 1993; 34(1): 1–4

    Article  PubMed  CAS  Google Scholar 

  19. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis: photochemotherapy follow-up study. Cancer 1994; 73(11): 2759–64

    Article  PubMed  CAS  Google Scholar 

  20. Mali-Gerrits MG, Gaasbeek D, Boezeman J, et al. Psoriasis therapy and the risk of skin cancers. Clin Exp Dermatol 1991; 16(2): 85–9

    Article  PubMed  CAS  Google Scholar 

  21. Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA): ametaanalysis. Arch Dermatol 1998; 134(12): 1582–5

    Article  PubMed  CAS  Google Scholar 

  22. Chuang TY, Heinrich LA, Schultz MD, et al. PUVA and skin cancer: a historical cohort study on 492 patients. J Am Acad Dermatol 1992; 26(2 Pt 1): 173–7

    Article  PubMed  CAS  Google Scholar 

  23. Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999; 141(1): 108–12

    Article  PubMed  CAS  Google Scholar 

  24. Zachariae H, Kragballe K, Sogaard H. Methotrexate induced liver cirrhosis: studies including serial liver biopsies during continued treatment. Br J Dermatol 1980; 102(4): 407–12

    Article  PubMed  CAS  Google Scholar 

  25. Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol 1999; 41(3 Pt 2): S25–8

    Article  PubMed  CAS  Google Scholar 

  26. Hecker D, Worsley J, Yueh G, et al. Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol 1999; 41(6): 927–30

    Article  PubMed  CAS  Google Scholar 

  27. Stern RS, Lange R. Non-melanoma skin cancer occurring in patients with PUVA five to ten years after first treatment. J Invest Dermatol 1988; 91(2): 120–4

    Article  PubMed  CAS  Google Scholar 

  28. Stern RS, Momtaz K. Skin typing for assessment of skin cancer risk and acute response to UV-B and oral methoxsalen photochemotherapy. Arch Dermatol 1984; 120(7): 869–73

    Article  PubMed  CAS  Google Scholar 

  29. Marrot L, Belaidi JP, Meunier JR, et al. The human melanocyte as a particular target for UVA radiation and an endpoint for photoprotection assessment. Photochem Photobiol 1999; 69(6): 686–93

    Article  PubMed  CAS  Google Scholar 

  30. Ley RD. Ultraviolet radiation A-induced precursors of cutaneous melanoma in Monodelphis domestica. Cancer Res 1997; 57(17): 3682–4

    PubMed  CAS  Google Scholar 

  31. Stern RS. Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation: the photochemotherapy follow-up study. N Engl J Med 1990; 322(16): 1093–7

    Article  PubMed  CAS  Google Scholar 

  32. Brown FS, Burnett JW, Robinson Jr HM. Cutaneous carcinoma following psoralen and long-wave ultraviolet radiation (PUVA) therapy for psoriasis. J Am Acad Dermatol 1980; 2(5): 393–5

    PubMed  CAS  Google Scholar 

  33. Sina B, Adrian RM. Multiple keratoacanthomas possibly induced by psoralens and ultraviolet A photochemotherapy. J Am Acad Dermatol 1983; 9(5): 686–8

    Article  PubMed  CAS  Google Scholar 

  34. Wolff K. Should PUVA be abandoned? N Engl J Med 1997; 336(15): 1090–1

    Article  PubMed  CAS  Google Scholar 

  35. Wang SQ, Setlow R, Berwick M, et al. Ultraviolet A and melanoma: a review. J Am Acad Dermatol 2001; 44(5): 837–46

    Article  PubMed  CAS  Google Scholar 

  36. Hitchins VM, Withrow TJ, Olvey KM, et al. The cytotoxic and mutagenic effects of UVA radiation on L5178Y mouse lymphoma cells. Photochem Photobiol 1986; 44(1): 53–7

    Article  PubMed  CAS  Google Scholar 

  37. Lundgren K, Wulf HC. Cytotoxicity and genotoxicity of UVA irradiation in Chinese hamster ovary cells measured by specific locus mutations, sister chromatid exchanges and chromosome aberrations. Photochem Photobiol 1988; 47(4): 559–63

    Article  PubMed  CAS  Google Scholar 

  38. Jones CA, Huberman E, Cunningham ML, et al. Mutagenesis and cytotoxicity in human epithelial cells by far- and near-ultraviolet radiations: action spectra. Radiat Res 1987; 110(2): 244–54

    Article  PubMed  CAS  Google Scholar 

  39. Wells RL, Han A. Action spectra for killing and mutation of Chinese hamster cells exposed to mid- and near-ultraviolet monochromatic light. Mutat Res 1984; 129(2): 251–8

    Article  PubMed  CAS  Google Scholar 

  40. Wenczl E, Van der Schans GP, Roza L, et al. (Pheo)melanin photosensitizes UVA-induced DNA damage in cultured human melanocytes. J Invest Dermatol 1998; 111(4): 678–82

    Article  PubMed  CAS  Google Scholar 

  41. Drobetsky EA, Turcotte J, Chateauneuf A. A role for ultraviolet A in solar mutagenesis. Proc Natl Acad Sci U S A 1995; 92(6): 2350–4

    Article  PubMed  CAS  Google Scholar 

  42. Setlow RB, Grist E, Thompson K, et al. Wavelengths effective in induction of malignant melanoma. Proc Natl Acad Sci U S A 1993; 90(14): 6666–70

    Article  PubMed  CAS  Google Scholar 

  43. Swerdlow AJ, Weinstock MA. Do tanning lamps cause melanoma? An epidemiologic assessment. J Am Acad Dermatol 1998; 38(1): 89–98

    Article  PubMed  CAS  Google Scholar 

  44. Westerdahl J, Ingvar C, Masback A, et al. Risk of cutaneous malignant melanoma in relation to use of sunbeds: further evidence for UV-A carcinogenicity. Br J Cancer 2000; 82(9): 1593–9

    Article  PubMed  CAS  Google Scholar 

  45. Wolf P, Schollnast R, Hofer A, et al. Malignant melanoma after psoralen and ultraviolet A (PUVA) therapy. Br J Dermatol 1998; 138(6): 1100–1

    Article  PubMed  CAS  Google Scholar 

  46. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA): the PUVA follow-up study. N Engl J Med 1997; 336(15): 1041–5

    Article  PubMed  CAS  Google Scholar 

  47. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44(5): 755–61

    Article  PubMed  CAS  Google Scholar 

  48. Whitmore SE, Morison WL. Melanoma after PUVA therapy for psoriasis. N Engl J Med 1997; 337(7): 502–3

    Article  PubMed  CAS  Google Scholar 

  49. Rahman P, Gladman DD, Schentag CT, et al. Excessive paternal transmission in psoriatic arthritis. Arthritis Rheum 1999; 42(6): 1228–31

    Article  PubMed  CAS  Google Scholar 

  50. Jeffes III EW, Weinstein GD. Methotrexate and other chemotherapeutic agents used to treat psoriasis. Dermatol Clin 1995; 13(4): 875–90

    PubMed  Google Scholar 

  51. Weinstein GD, Goldfaden G, Frost P. Methotrexate: mechanism of action on DNA synthesis in psoriasis. Arch Dermatol 1971; 104(3): 236–43

    Article  PubMed  CAS  Google Scholar 

  52. Parnham MJ. Antirheumatic agents and leukocyte recruitment: new light on the mechanism of action of oxaceprol. Biochem Pharmacol 1999; 58(2): 209–15

    Article  PubMed  CAS  Google Scholar 

  53. Zachariae H, Grunnet E, Sogaard H. Liver biopsy in methotrexate-treated psoriatics: a re-evalution. Acta Derm Venereol 1975; 55(4): 291–6

    PubMed  CAS  Google Scholar 

  54. Nyfors A. Liver biopsies from psoriatics related to methotrexate therapy: 3. Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand [A] 1977; 85(4): 511–8

    CAS  Google Scholar 

  55. Robinson JK, Baughman RD, Auerbach R, et al. Methotrexate hepatotoxicity in psoriasis: consideration of liver biopsies at regular intervals. Arch Dermatol 1980; 116(4): 413–5

    Article  PubMed  CAS  Google Scholar 

  56. Zachariae H, Sogaard H. Methotrexate-induced liver cirrhosis: a follow-up. Dermatologica 1987; 175(4): 178–82

    Article  PubMed  CAS  Google Scholar 

  57. Roenigk Jr HH, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38(3): 478–85

    Article  PubMed  Google Scholar 

  58. Malatjalian DA, Ross JB, Williams CN, et al. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996; 10(6): 369–75

    PubMed  CAS  Google Scholar 

  59. Weinstein G, Roenigk H, Maibach H, et al. Psoriasis-liver methotrexate interactions. Arch Dermatol 1973 108: 36–42

    Article  Google Scholar 

  60. Lanse SB, Arnold GL, Gowans JD, et al. Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis: an acceptable risk/benefit ratio. Dig Dis Sci 1985; 30(2): 104–9

    Article  PubMed  CAS  Google Scholar 

  61. Boffa MJ, Chalmers RJ, Haboubi NY, et al. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995; 133(5): 774–8

    Article  PubMed  CAS  Google Scholar 

  62. Dooren-Greebe RJ, Kuijpers AL, Mulder J, et al. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994; 130(2): 204–10

    Article  PubMed  Google Scholar 

  63. Newman M, Auerbach R, Feiner H, et al. The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment: improvement in liver abnormalities after cessation of treatment. Arch Dermatol 1989; 125(9): 1218–24

    Article  PubMed  CAS  Google Scholar 

  64. van de Kerkhof PC, Hoefnagels WH, van Haelst UJ, et al. Methotrexate maintenance therapy and liver damage in psoriasis. Clin Exp Dermatol 1985; 10(3): 194–200

    Article  PubMed  Google Scholar 

  65. Zachariae H. Liver biopsies and methotrexate: a time for reconsideration? J Am Acad Dermatol 2000; 42(3): 531–4

    Article  PubMed  CAS  Google Scholar 

  66. Boffa MJ, Smith A, Chalmers RJ, et al. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol 1996; 135(4): 538–44

    Article  PubMed  CAS  Google Scholar 

  67. Zachariae H, Aslam HM, Bjerring P, et al. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. J Am Acad Dermatol 1991; 25(1 Pt 1): 50–3

    Article  PubMed  CAS  Google Scholar 

  68. Casserly CM, Stange KC, Chren MM. Severe megaloblastic anemia in a patient receiving low-dose methotrexate for psoriasis. J Am Acad Dermatol 1993; 29(3): 477–80

    Article  PubMed  CAS  Google Scholar 

  69. Wolverton SE. Systemic drug therapy for psoriasis: the most critical issues. Arch Dermatol 1991; 127(4): 565–8

    Article  PubMed  CAS  Google Scholar 

  70. Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33(1): 9–18

    Article  PubMed  CAS  Google Scholar 

  71. van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44(7): 1515–24

    Article  PubMed  Google Scholar 

  72. Abel EA, Farber EM. Pancytopenia following low-dose methotrexate therapy [editorial]. JAMA 1988; 259(24): 3612

    Article  PubMed  CAS  Google Scholar 

  73. Thomas DR, Dover JS, Camp RD. Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole. J Am Acad Dermatol 1987; 17(6): 1055–6

    Article  PubMed  CAS  Google Scholar 

  74. Shiroky JB, Frost A, Skelton JD, et al. Complications of immunosuppression associated with weekly low dose methotrexate. J Rheumatol 1991; 18(8): 1172–5

    PubMed  CAS  Google Scholar 

  75. Kamel OW, van de RM, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993; 328(18): 1317–21

    Article  PubMed  CAS  Google Scholar 

  76. Ellman MH, Hurwitz H, Thomas C, et al. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol 1991; 18(11): 1741–3

    PubMed  CAS  Google Scholar 

  77. Santana V, Rose NR. Neoplastic lymphoproliferation in autoimmune disease: an updated review. Clin Immunol Immunopathol 1992; 63(3): 205–13

    Article  PubMed  CAS  Google Scholar 

  78. Marlier S, Chagnon A, Brocq O, et al. Lymphoma induced by low-dose methotrexate in rheumatoid arthritis with severe lymphopenia.. Ann Med Interne (Paris) 1995; 146(3): 206–8

    CAS  Google Scholar 

  79. Kingsmore SF, Hall BD, Allen NB, et al. Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. J Rheumatol 1992; 19(9): 1462–5

    PubMed  CAS  Google Scholar 

  80. Liote F, Pertuiset E, Cochand-Priollet B, et al. Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis: role of Epstein-Barr virus infection. J Rheumatol 1995; 22(6): 1174–8

    PubMed  CAS  Google Scholar 

  81. Viraben R, Brousse P, Lamant L. Reversible cutaneous lymphoma occurring during methotrexate therapy. Br J Dermatol 1996; 135(1): 116–8

    Article  PubMed  CAS  Google Scholar 

  82. Bachman TR, Sawitzke AD, Perkins SL, et al. Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum 1996; 39(2): 325–9

    Article  PubMed  CAS  Google Scholar 

  83. van de RM, Cleary ML, Variakojis D, et al. Epstein-Barr virus clonality in lymphomas occurring in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39(4): 638–42

    Article  Google Scholar 

  84. Thomason RW, Craig FE, Banks PM, et al. Epstein-Barr virus and lymphoproliferation in methotrexate-treated rheumatoid arthritis. Mod Pathol 1996; 9(3): 261–6

    PubMed  CAS  Google Scholar 

  85. Paul C, Le Tourneau A, Cayuela JM, et al. Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. Arch Dermatol 1997; 133(7): 867–71

    Article  PubMed  CAS  Google Scholar 

  86. Phillips TJ, Jones DH, Baker H. Pulmonary complications following methotrexate therapy. J Am Acad Dermatol 1987; 16(2 Pt 1): 373–5

    Article  PubMed  CAS  Google Scholar 

  87. RoenigkJr HH, Auerbach R, Maibach HI, et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19(1 Pt1): 145–56

    Article  PubMed  Google Scholar 

  88. Cottin V, Tebib J, Massonnet B, et al. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 1996; 109(4): 933–8

    Article  PubMed  CAS  Google Scholar 

  89. Madhok R, Muller SA, Dicken CH. Treatment of psoriasis with etretin: a preliminary report. Mayo Clin Proc 1987; 62(12): 1084–9

    PubMed  CAS  Google Scholar 

  90. Geiger JM, Saurat JH. Acitretin and etretinate: how and when they should be used. Dermatol Clin 1993; 11(1): 117–29

    PubMed  CAS  Google Scholar 

  91. Roenigk Jr HH. Acitretin combination therapy. J Am Acad Dermatol 1999; 41(3 Pt 2): S18–21

    Article  PubMed  Google Scholar 

  92. Orfanos CE. Treatment of psoriasis with retinoids: present status. Cutis 1999; 64(5): 347–53

    PubMed  CAS  Google Scholar 

  93. Abdullah AN, Keczkes K. Cutaneous and ocular side-effects of PUVA photochemotherapy: a 10-year follow-up study. Clin Exp Dermatol 1989; 14(6): 421–4

    Article  PubMed  CAS  Google Scholar 

  94. Saurat JH. Systemic retinoids: what’s new? Dermatol Clin 1998; 16(2): 331–40

    Article  PubMed  CAS  Google Scholar 

  95. Gollnick HP. Oral retinoids: efficacy and toxicity in psoriasis. Br J Dermatol 1996; 135Suppl. 49: 6–17

    Article  PubMed  CAS  Google Scholar 

  96. Chou RC, Wyss R, Huselton CA, et al. A potentially new metabolic pathway: ethyl esterification of acitretin. Xenobiotica 1992; 22(8): 993–1002

    Article  PubMed  CAS  Google Scholar 

  97. Laugier JP, de Sousa G, Bun H, et al. Acitretin biotransformation into etretinate: role of ethanol on in vitro hepatic metabolism. Dermatology 1994; 188(2): 122–5

    Article  PubMed  CAS  Google Scholar 

  98. Larsen FG, Jakobsen P, Knudsen J, et al. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 1993; 100(5): 623–7

    Article  PubMed  CAS  Google Scholar 

  99. Sankaranarayanan R, Mathew B. Retinoids as cancer-preventive agents. IARC Sci Publ 1996; 139: 47–59

    PubMed  CAS  Google Scholar 

  100. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993; 328(1): 15–20

    Article  PubMed  CAS  Google Scholar 

  101. Hudson-Peacock MJ, Angus B, Farr PM. Response of PUVA-induced keratoses to etretinate. J Am Acad Dermatol 1996; 35(1): 120–3

    Article  PubMed  CAS  Google Scholar 

  102. David M, Hodak E, Lowe NJ. Adverse effects of retinoids. Med Toxicol Adverse Drug Exp 1988; 3(4): 273–88

    PubMed  CAS  Google Scholar 

  103. Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 1999; 41(3 Pt 2): S7–S12

    Article  PubMed  CAS  Google Scholar 

  104. Goldfarb MT, Ellis CN, Voorhees JJ. Short-term and long-term considerations in the management of psoriasis with retinoids. Dermatologica 1987; 175Suppl. 1: 100–6

    Article  PubMed  Google Scholar 

  105. Prendiville J, Bingham EA, Burrows D. Premature epiphyseal closure: a complication of etretinate therapy in children. J Am Acad Dermatol 1986; 15(6): 1259–62

    Article  PubMed  CAS  Google Scholar 

  106. Roenigk Jr HH. Liver toxicity of retinoid therapy. J Am Acad Dermatol 1988; 19(1 Pt 2): 199–208

    Article  PubMed  Google Scholar 

  107. Ellis CN, Voorhees JJ. Etretinate therapy. J Am Acad Dermatol 1987; 16(2 Pt 1): 267–91

    Article  PubMed  CAS  Google Scholar 

  108. Camuto P, Shupack J, Orbuch P, et al. Long-term effects of etretinate on the liver in psoriasis. Am J Surg Pathol 1987; 11(1): 30–7

    Article  PubMed  CAS  Google Scholar 

  109. Roenigk Jr HH, Gibstine C, Glazer S, et al. Serial liver biopsies in psoriatic patients receiving long-term etretinate. Br J Dermatol 1985; 112(1): 77–81

    Article  PubMed  Google Scholar 

  110. Koo J, Nguyen Q, Gambla C. Advances in psoriasis therapy. Adv Dermatol 1997; 12: 47–72

    PubMed  CAS  Google Scholar 

  111. Roenigk Jr HH, Callen JP, Guzzo CA, et al. Effects of acitretin on the liver. J Am Acad Dermatol 1999; 41(4): 584–8

    Article  PubMed  Google Scholar 

  112. Lowe NJ, Lazarus V, Matt L. Systemic retinoid therapy for psoriasis. J Am Acad Dermatol 1988; 19(1 Pt 2): 186–91

    Article  PubMed  CAS  Google Scholar 

  113. Gupta AK, Goldfarb MT, Ellis CN, et al. Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 1989; 20(6): 1088–93

    Article  PubMed  CAS  Google Scholar 

  114. Bartecchi CE, Mastro ER, Swarts CW. Acute hemorrhagic pancreatitis with hypertriglyceridemia. Rocky Mt Med J 1976; 73(2): 95–8

    PubMed  CAS  Google Scholar 

  115. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256(20): 2823–8

    Article  PubMed  CAS  Google Scholar 

  116. Ader JL, Rostaing L. Cyclosporin nephrotoxicity: pathophysiology and comparison with FK-506. Curr Opin Nephrol Hypertens 1998; 7(5): 539–45

    Article  PubMed  CAS  Google Scholar 

  117. Lubetzki C, Sanson M, Cohen D, et al. Benign intracranial hypertension and minocycline. Rev Neurol (Paris) 1988; 144(3): 218–20

    CAS  Google Scholar 

  118. Moskowitz Y, Leibowitz E, Ronen M, et al. Pseudotumor cerebri induced by vitamin A combined with minocycline. Ann Ophthalmol 1993; 25(8): 306–8

    PubMed  CAS  Google Scholar 

  119. Okada N, Nomura M, Morimoto S, et al. Bone mineral density of the lumbar spine in psoriatic patients with long term etretinate therapy. J Dermatol 1994; 21(5): 308–11

    PubMed  CAS  Google Scholar 

  120. Saurat JH. Side effects of systemic retinoids and their clinical management. J Am Acad Dermatol 1992; 27(6 Pt 2): S23–8

    Article  PubMed  CAS  Google Scholar 

  121. Vahlquist A. Long-term safety of retinoid therapy. J Am Acad Dermatol 1992; 27(6 Pt 2): S29–33

    Article  PubMed  CAS  Google Scholar 

  122. Halkier-Sorensen L, Andresen J. A retrospective study of bone changes in adults treated with etretinate. J Am Acad Dermatol 1989; 20(1): 83–7

    Article  PubMed  CAS  Google Scholar 

  123. Gerber LH, Helfgott RK, Gross EG, et al. Vertebral abnormalities associated with synthetic retinoid use. J Am Acad Dermatol 1984; 10(5 Pt 1): 817–23

    Article  PubMed  CAS  Google Scholar 

  124. Silverman AK, Ellis CN, Voorhees JJ. Hypervitaminosis A syndrome: a paradigm of retinoid side effects. J Am Acad Dermatol 1987; 16(5 Pt 1): 1027–39

    Article  PubMed  CAS  Google Scholar 

  125. Melnik B, Gluck S, Jungblut RM, et al. Retrospective radiographic study of skeletal changes after long-term etretinate therapy. Br J Dermatol 1987; 116(2): 207–12

    Article  PubMed  CAS  Google Scholar 

  126. Dooren-Greebe RJ, Lemmens JA, De Boo T, et al. Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities. Br J Dermatol 1996; 134(1): 71–6

    Article  PubMed  Google Scholar 

  127. Ho VC, Griffiths CE, Berth-Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001; 44(4): 643–51

    Article  PubMed  CAS  Google Scholar 

  128. Finzi AF, Ippolito F, Panconesi E, et al. Cyclosporin therapy in psoriasis: recommendations for treatment. Italian Multicenter Study Group on Cyclosporin in Psoriasis. Dermatology 1993; 187Suppl. 1: 38–40

    Google Scholar 

  129. Koo J, Lee J. Cyclosporine: what clinicians need to know. Dermatol Clin 1995; 13(4): 897–907

    PubMed  CAS  Google Scholar 

  130. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41(1): 51–9

    Article  PubMed  CAS  Google Scholar 

  131. Korstanje MJ. How to improve the risk-benefit ratio of cyclosporin therapy for psoriasis. Clin Exp Dermatol 1992; 17(1): 16–9

    Article  PubMed  CAS  Google Scholar 

  132. Levell NJ, Shuster S, Munro CS, et al. Remission of ordinary psoriasis following a short clearance course of cyclosporin. Acta Derm Venereol 1995; 75(1): 65–9

    PubMed  CAS  Google Scholar 

  133. Zachariae H, Kragballe K, Hansen HE, et al. Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol 1997; 136(4): 531–5

    Article  PubMed  CAS  Google Scholar 

  134. Ruiz P, Kolbeck PC, Scroggs MW, et al. Cyclosporine therapy and the development of interstitial fibrosis in renal allografts. Transplant Proc 1988; 20 (3Suppl. 3): 807–11

    Google Scholar 

  135. Ruiz P, Kolbeck PC, Scroggs MW, et al. Associations between cyclosporine therapy and interstitial fibrosis in renal allografts. Transplantation 1988; 45(1): 91–5

    Article  PubMed  CAS  Google Scholar 

  136. Kopp JB, Klotman PE. Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol 1990; 1(2): 162–79

    PubMed  CAS  Google Scholar 

  137. Hutchinson IV. An endothelin-transforming growth factor beta pathway in the nephrotoxicity of immunosuppressive drugs. Curr Opin Nephrol Hypertens 1998; 7 (6): 665–71

    Google Scholar 

  138. Finn WF. FK506 nephrotoxicity. Ren Fail 1999; 21(3-4): 319–29

    Article  PubMed  CAS  Google Scholar 

  139. Powles AV, Cook T, Hulme B, et al. Renal function and biopsy findings after 5 years’ treatment with low-dose cyclosporin for psoriasis. Br J Dermatol 1993; 128(2): 159–65

    Article  PubMed  CAS  Google Scholar 

  140. Laburte C, Grossman R, Abi-Rached J, et al. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994; 130(3): 366–75

    Article  PubMed  CAS  Google Scholar 

  141. Lowe NJ, Wieder JM, Rosenbach A, et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 1996; 35 (5Pt 1): 710–9

    Article  Google Scholar 

  142. London NJ, Farmery SM, Will EJ, et al. Risk of neoplasia in renal transplant patients. Lancet 1995; 346(8972): 403–6

    Article  PubMed  CAS  Google Scholar 

  143. Hiesse C, Kriaa F, Rieu P, et al. Incidence and type of malignancies occurring after renal transplantation in conventionally and cyclosporine-treated recipients: analysis of a 20-year period in 1600 patients. Transplant Proc 1995; 27(1): 972–4

    PubMed  CAS  Google Scholar 

  144. Kohler LD, Kautzky F, Vogt HJ. Multiple cutaneous neoplasms in cyclosporine therapy after kidney transplantation. Hautarzt 1995; 46(9): 638–42

    Article  PubMed  CAS  Google Scholar 

  145. Chuang FR, Hsieh H, Hsu KT, et al. Increasing transplant cancer patient survival by conversion of immunosuppressive agents. Transplant Proc 1996; 28(3): 1346–7

    PubMed  CAS  Google Scholar 

  146. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001; 358(9287): 1042–5

    Article  PubMed  CAS  Google Scholar 

  147. Petzelbauer P, Honigsmann H, Langer K, et al. Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis. Br J Dermatol 1990; 123(5): 641–7

    Article  PubMed  CAS  Google Scholar 

  148. Rosenbaum MM, Roenigk Jr HH. Treatment of generalized pustular psoriasis with etretinate (Ro 10-9359) and methotrexate. J Am Acad Dermatol 1984; 10(2 Pt 2): 357–61; 17

    Article  PubMed  CAS  Google Scholar 

  149. Vanderveen EE, Ellis CN, Campbell JP, et al. Methotrexate and etretinate as concurrent therapies in severe psoriasis. Arch Dermatol 1982; 118(9): 660–2

    Article  PubMed  CAS  Google Scholar 

  150. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28(3): 454–9

    Article  PubMed  CAS  Google Scholar 

  151. Menter MA, See JA, Amend WJ, et al. Proceedings of the Psoriasis Combination and Rotation Therapy Conference; 1994 Oct 7-9; Deer Valley (UT). J Am Acad Dermatol 1996; 34(2 Pt 1): 315–21

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the contents of this manuscript.

Author information

Authors and Affiliations

  1. Department of Dermatology, Northwestern University Medical School, 675 N. St. Clair St, Suite 19-150, Chicago, Illinois, IL60611, USA

    Stacy L. McClure, Jayme Valentine &  Kenneth B. Gordon

Authors
  1. Stacy L. McClure
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jayme Valentine
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenneth B. Gordon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth B. Gordon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McClure, S.L., Valentine, J. & Gordon, K.B. Comparative Tolerability of Systemic Treatments for Plaque-Type Psoriasis. Drug-Safety 25, 913–927 (2002). https://doi.org/10.2165/00002018-200225130-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200225130-00003

Keywords

Search

Navigation